Claim

In the same phase 1b/2 study, the regimen produced a 95% disease-control rate among the 40 analyzed participants.

Type QUANTITATIVE · truth-evaluable: yes · status at snapshot: ACTIVE · created seq 14572 · qualifiers {"population":"The study's 40 analyzed participants with previously untreated HER2-positive advanced biliary tract cancer.","denominator":"40 participants; disease control includes complete response, partial response, and stable disease under the study definition."}

Referenced 115 times: checked 2, looked up by assistants 1, viewed 77, shared 35. A count of attention, not evidence.

Topics

Medicine · 1efd24fe Public health · 1efd24fe

Assessment

Supported

Score: 0.9781 under ledger-default@0.3.0 at snapshot 27745

2 of 4 review checks done · 1 counted · 1 by the author only

2 independent evidence lineages · review checks 1 of 4 · stability HIGH

Main unresolved issue: 7 counted evidence items have no independence review; repeats of one origin may be counted as several coverage:cedeaa73-ee17-85bf-8f12-16e466326450

Not yet independently audited.Evidence reviewed so far supports this claim, but only 1 of 4 review checks has been done.A quoted passage from nature.com was not found on the page when Galedra fetched it.

Why?

Strongest counted support: The abstract directly reports 55% objective response and 95% disease control among 40 participants. weight 2.000000 evidence

Suppressed as dependent: The excerpt explicitly reports a 95% disease-control rate in the study, alongside response data from 40 participants.

Review gaps: qualifiers reviewed, opposing search done, independence reviewed

What would most change this: One independent, direct measurement that contradicts this claim would move it from Supported to Supported.

Hide calculation

0.9781 under ledger-default@0.3.0 at snapshot 27745 · state Supported · Review checks: 1 of 4 · stability HIGH · 7 sources, 2 independent lineages

Model ledger-default@0.3.0 (the default model, not the answer) · snapshot 27745 · trace sha256:1983d4092e53206f2d1ef02489099e2e099c65fdc68413e2a52c918a361e15d9

Last changed at entry seq 25043; nothing logged since has borne on this claim.

How the number was reached

Each counted link is weighed by multiplying the factors the model declares; a factor it does not declare is not shown. Every factor name below links to what that number means.

Link	Working	Weight	Counted as
39751f6c qualify	relevance DIRECT 2.0 × observation DIRECT_TEXT 0.9 × interpretation 0 steps, 1 − 0.15 × 0 1.000000 × authenticity UNVERIFIED 1.0 × extraction UNVERIFIED 1.0 × provenance INDEPENDENT 1.0 × edition NAMED_OR_UNRELATED 1	1.800000	0.000000 (non directional)
655485fb support	relevance DIRECT 2.0 × observation DIRECT_TEXT 0.9 × interpretation 0 steps, 1 − 0.15 × 0 1.000000 × authenticity UNVERIFIED 1.0 × extraction UNVERIFIED 1.0 × provenance INDEPENDENT 1.0 × edition NAMED_OR_UNRELATED 1	1.800000	0.000000 (dependent strongest only, kept fee9b649)
fee9b649 support	relevance DIRECT 2.0 × observation MEASUREMENT 1.0 × interpretation 0 steps, 1 − 0.15 × 0 1.000000 × authenticity UNVERIFIED 1.0 × extraction UNVERIFIED 1.0 × provenance INDEPENDENT 1.0 × edition NAMED_OR_UNRELATED 1	2.000000	2.000000
a80d468e qualify	relevance DIRECT 2.0 × observation MEASUREMENT 1.0 × interpretation 0 steps, 1 − 0.15 × 0 1.000000 × authenticity UNVERIFIED 1.0 × extraction UNVERIFIED 1.0 × provenance INDEPENDENT 1.0 × edition NAMED_OR_UNRELATED 1	2.000000	0.000000 (non directional)
8d090d08 qualify	relevance MODERATE 0.6 × observation DIRECT_TEXT 0.9 × interpretation 0 steps, 1 − 0.15 × 0 1.000000 × authenticity UNVERIFIED 1.0 × extraction UNVERIFIED 1.0 × provenance INDEPENDENT 1.0 × edition NAMED_OR_UNRELATED 1	0.540000	0.000000 (non directional)
8d41d263 qualify	relevance DIRECT 2.0 × observation DIRECT_TEXT 0.9 × interpretation 0 steps, 1 − 0.15 × 0 1.000000 × authenticity UNVERIFIED 1.0 × extraction UNVERIFIED 1.0 × provenance INDEPENDENT 1.0 × edition NAMED_OR_UNRELATED 1	1.800000	0.000000 (non directional)
8e49a300 support	relevance DIRECT 2.0 × observation DIRECT_TEXT 0.9 × interpretation 0 steps, 1 − 0.15 × 0 1.000000 × authenticity UNVERIFIED 1.0 × extraction UNVERIFIED 1.0 × provenance INDEPENDENT 1.0 × edition NAMED_OR_UNRELATED 1	1.800000	1.800000

prior 0.50 → log-odds 0.000000 + 3.800000 (the counted weights) = 3.800000 → probability 0.9781

Under neighbouring settings of the same model: 0.9346 to 0.9929, a spread of 0.0583.

Half-even rounding, six places for weights and four for the probability. The same inputs under the same model reproduce this exactly; that is what the trace hash above is for. How a score is worked out explains every factor, why it is there, and what the model sets it to.

Your view

Registered views

Nobody has registered a view yet.

Registered views are personal belief, not evidence: they never change Galedra's assessment. Affiliations are self-declared and shown only for groups of 5 or more.

Checked as part of

Statements this claim was broken out of. The claim is scored on its own; a statement's reading only counts its claims.

“In the same phase 1b/2 study, the regimen produced a 95% disease-control rate among the 40 analyzed participants.” · 1 claim · 29 September 2026
“In a South Korean phase 1b/2 study of 40 participants with previously untreated HER2-positive advanced biliary tract cancer, a...” · 2 claims · 28 September 2026

Evidence for

The abstract directly reports 55% objective response and 95% disease control among 40 participants.

From Trastuzumab plus nivolumab with gemcitabine and cisplatin as first-line therapy for HER2-positive unresectable biliary tract cancer: a phase 1b/2 trial Read 2026-09-28 Relevance DIRECT Steps 0 Counted

The abstract directly states the 95% disease-control rate.
The excerpt explicitly reports a 95% disease-control rate in the study, alongside response data from 40 participants.

From Trastuzumab plus nivolumab with gemcitabine and cisplatin as first-line therapy for HER2-positive unresectable biliary tract cancer: a phase 1b/2 trial Read 2026-09-28 Relevance DIRECT Steps 0 Counted

The quoted abstract directly states the disease-control rate.
The primary trial report states that the regimen produced a 95% disease-control rate among 40 participants.

From Trastuzumab plus nivolumab with gemcitabine and cisplatin as first-line therapy for HER2-positive unresectable biliary tract cancer: a phase 1b/2 trial Read 2026-09-29 Relevance DIRECT Steps 0 Counted

Primary Nature Medicine report; added as direct support for the existing claim.

Evidence against

None.

Qualifications

The result comes from an open-label single-arm phase 1b/2 study at 12 South Korean centers in HER2-positive advanced biliary cancer.

From Trastuzumab plus nivolumab with gemcitabine and cisplatin as first-line therapy for HER2-positive unresectable biliary tract cancer: a phase 1b/2 trial Read 2026-09-29 Relevance DIRECT Steps 0 Counted

Adds study design, jurisdiction, and disease-population limits.
The absence of a randomized control arm limits definitive comparison with standard care.

From Trastuzumab plus nivolumab with gemcitabine and cisplatin as first-line therapy for HER2-positive unresectable biliary tract cancer: a phase 1b/2 trial Read 2026-09-29 Relevance MODERATE Steps 0 Counted

Adds the authors’ limitation on causal comparison.
Disease control included confirmed complete response, partial response, or stable disease lasting at least four weeks.

From Trastuzumab plus nivolumab with gemcitabine and cisplatin as first-line therapy for HER2-positive unresectable biliary tract cancer: a phase 1b/2 trial Read 2026-09-29 Relevance DIRECT Steps 0 Counted

Defines what counted as disease control.
Participants were treatment-naive, and gallbladder cancer comprised 72.5% of the analyzed population.

From Trastuzumab plus nivolumab with gemcitabine and cisplatin as first-line therapy for HER2-positive unresectable biliary tract cancer: a phase 1b/2 trial Read 2026-09-29 Relevance DIRECT Steps 0 Counted

Adds treatment-history and subtype composition qualifiers.

Suppressed as dependent

Evidence	Group	Kept instead
3b7a37b0		fee9b649

Inferences

Concluded from

None.

Used as a premise in

None.

An inference is interpretation, not evidence: it never changes the assessment of its conclusion. Each premise is a claim with its own evidence.

Threads

None. Threads are for disagreements about how a determination was made — a statement whose figures are not in the passage it rests on, two sources that may share an origin. Something about the world belongs in the evidence above.

Claim edges

None. Edges are stored and displayed; v0.1 does not propagate probability across them.

Review checklist

Review checks: 1 of 4

2 checks by this claim's own author, alongside the independent review above. 1 QUALIFIER CHECK · 1 EVIDENCE VERIFICATION. A check by the person who recorded a claim does not raise its review coverage.

Check	Done	By
qualifiers reviewed	no
opposing search done	no
independence reviewed	no
primary source reviewed	yes	39751f6c, 655485fb, fee9b649, a80d468e, 8d090d08, 8d41d263, 8e49a300

Summary

Supported. The main support is: The abstract directly reports 55% objective response and 95% disease control among 40 participants. 3eada94f

1 further item repeats the same origin and is not independent evidence. 3b7a37b0

Qualifier: Disease control included confirmed complete response, partial response, or stable disease lasting at least four weeks. 5c5602d2

Qualifier: Participants were treatment-naive, and gallbladder cancer comprised 72.5% of the analyzed population. 462e26de

Qualifier: The absence of a randomized control arm limits definitive comparison with standard care. 6ab9cc69

Qualifier: The result comes from an open-label single-arm phase 1b/2 study at 12 South Korean centers in HER2-positive advanced biliary cancer. 096cb7e0

Generated by stub-v0.1; every sentence cites graph ids.

Contribution history

seq	event	detail
14572	APPENDED
14573	ACCEPT	AUTOMATIC_AFTER_VALIDATION
14584	LINK_EVIDENCE	by 1efd24fe (accepted)
14588	TASK_RESULT	by 1efd24fe (accepted)
15122	TASK_RESULT	by 1efd24fe (accepted)
18944	LINK_EVIDENCE	by 1efd24fe (accepted)

Score trace

{
  "claim": "cedeaa73-ee17-85bf-8f12-16e466326450",
  "links": [
    {
      "link": "1d308a6f-758d-872c-bb78-5f6539751f6c",
      "group": null,
      "reason": "non_directional",
      "edition": "NAMED_OR_UNRELATED",
      "evidence": "13748634-0d59-8c3c-8713-d3c25c5602d2",
      "direction": "QUALIFY",
      "magnitude": "1.800000",
      "relevance": "DIRECT",
      "extraction": "UNVERIFIED",
      "provenance": "INDEPENDENT",
      "observation": "DIRECT_TEXT",
      "source_type": "PRIMARY_TEXT",
      "authenticity": "UNVERIFIED",
      "audit_confirmed": false,
      "effective_weight": "0.000000",
      "interpretive_steps": 0
    },
    {
      "kept": "8184b5e5-b057-808d-b2f1-0760fee9b649",
      "link": "43ce321c-4a91-84f7-82fe-5b31655485fb",
      "group": null,
      "reason": "dependent_strongest_only",
      "edition": "NAMED_OR_UNRELATED",
      "evidence": "317d6133-063c-8c71-af99-48983b7a37b0",
      "direction": "SUPPORT",
      "magnitude": "1.800000",
      "relevance": "DIRECT",
      "extraction": "UNVERIFIED",
      "provenance": "INDEPENDENT",
      "observation": "DIRECT_TEXT",
      "source_type": "PRIMARY_TEXT",
      "authenticity": "UNVERIFIED",
      "audit_confirmed": false,
      "effective_weight": "0.000000",
      "interpretive_steps": 0
    },
    {
      "link": "8184b5e5-b057-808d-b2f1-0760fee9b649",
      "group": null,
      "edition": "NAMED_OR_UNRELATED",
      "evidence": "5b031266-31ff-8aae-89ec-0d3d3eada94f",
      "direction": "SUPPORT",
      "magnitude": "2.000000",
      "relevance": "DIRECT",
      "extraction": "UNVERIFIED",
      "provenance": "INDEPENDENT",
      "observation": "MEASUREMENT",
      "source_type": "PRIMARY_TEXT",
      "authenticity": "UNVERIFIED",
      "audit_confirmed": false,
      "effective_weight": "2.000000",
      "interpretive_steps": 0
    },
    {
      "link": "96e77139-d93b-88b2-92d8-3b3ba80d468e",
      "group": null,
      "reason": "non_directional",
      "edition": "NAMED_OR_UNRELATED",
      "evidence": "b33f48bc-a281-835f-979c-9979462e26de",
      "direction": "QUALIFY",
      "magnitude": "2.000000",
      "relevance": "DIRECT",
      "extraction": "UNVERIFIED",
      "provenance": "INDEPENDENT",
      "observation": "MEASUREMENT",
      "source_type": "PRIMARY_TEXT",
      "authenticity": "UNVERIFIED",
      "audit_confirmed": false,
      "effective_weight": "0.000000",
      "interpretive_steps": 0
    },
    {
      "link": "98d93830-fbd6-8402-8648-49b68d090d08",
      "group": null,
      "reason": "non_directional",
      "edition": "NAMED_OR_UNRELATED",
      "evidence": "a31e9c5f-c58a-83c6-90de-f1b56ab9cc69",
      "direction": "QUALIFY",
      "magnitude": "0.540000",
      "relevance": "MODERATE",
      "extraction": "UNVERIFIED",
      "provenance": "INDEPENDENT",
      "observation": "DIRECT_TEXT",
      "source_type": "PRIMARY_TEXT",
      "authenticity": "UNVERIFIED",
      "audit_confirmed": false,
      "effective_weight": "0.000000",
      "interpretive_steps": 0
    },
    {
      "link": "d6e90e61-703a-8ae7-a7d8-11888d41d263",
      "group": null,
      "reason": "non_directional",
      "edition": "NAMED_OR_UNRELATED",
      "evidence": "4e1203d4-7823-8938-a7cd-bf65096cb7e0",
      "direction": "QUALIFY",
      "magnitude": "1.800000",
      "relevance": "DIRECT",
      "extraction": "UNVERIFIED",
      "provenance": "INDEPENDENT",
      "observation": "DIRECT_TEXT",
      "source_type": "PRIMARY_TEXT",
      "authenticity": "UNVERIFIED",
      "audit_confirmed": false,
      "effective_weight": "0.000000",
      "interpretive_steps": 0
    },
    {
      "link": "f4858e11-1e5a-8a18-af6f-36138e49a300",
      "group": null,
      "edition": "NAMED_OR_UNRELATED",
      "evidence": "cfe0ded4-3830-86b9-a0ba-bcce05cc43cd",
      "direction": "SUPPORT",
      "magnitude": "1.800000",
      "relevance": "DIRECT",
      "extraction": "UNVERIFIED",
      "provenance": "INDEPENDENT",
      "observation": "DIRECT_TEXT",
      "source_type": "PRIMARY_TEXT",
      "authenticity": "UNVERIFIED",
      "audit_confirmed": false,
      "effective_weight": "1.800000",
      "interpretive_steps": 0
    }
  ],
  "model": "ledger-default@0.3.0",
  "prior": "0.50",
  "variants": {
    "spread": "0.0583",
    "permissive": "0.9929",
    "conservative": "0.9346"
  },
  "code_hash": "sha256:c61a6fdf35a754a0d7e958df149036a083c0eaeb7d2d2e52704ec32b0c36def7",
  "contested": false,
  "stability": "HIGH",
  "claim_type": "QUANTITATIVE",
  "config_hash": "sha256:86768038080b8ab5233f1e4b7aba10af05b5bb44caa432095150b90e81209809",
  "probability": "0.9781",
  "provisional": true,
  "evidence_sum": "3.800000",
  "snapshot_seq": 25043,
  "prior_log_odds": "0.000000",
  "support_groups": 2,
  "model_dependent": false,
  "review_coverage": "0.25",
  "truth_evaluable": true,
  "assessment_state": "SUPPORTED",
  "review_checklist": {
    "qualifiers_reviewed": {
      "by": [],
      "ok": false
    },
    "opposing_search_done": {
      "by": [],
      "ok": false
    },
    "independence_reviewed": {
      "by": [],
      "ok": false
    },
    "primary_source_reviewed": {
      "by": [
        "1d308a6f-758d-872c-bb78-5f6539751f6c",
        "43ce321c-4a91-84f7-82fe-5b31655485fb",
        "8184b5e5-b057-808d-b2f1-0760fee9b649",
        "96e77139-d93b-88b2-92d8-3b3ba80d468e",
        "98d93830-fbd6-8402-8648-49b68d090d08",
        "d6e90e61-703a-8ae7-a7d8-11888d41d263",
        "f4858e11-1e5a-8a18-af6f-36138e49a300"
      ],
      "ok": true
    }
  },
  "contradict_groups": 0,
  "rounding_boundary": false,
  "posterior_log_odds": "3.800000",
  "not_applicable_reason": null,
  "independence_unreviewed": 7
}